Drug Profile
Farletuzumab companion diagnostic - Fujirebio Diagnostics
Alternative Names: CA125 II assay - Fujirebio Diagnostics; CA125 II companion diagnostic; Lumipulse® G CA125-II assay - Fujirebio Diagnostics; MORAb-003 companion diagnosticLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Fujirebio Diagnostics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Diagnosis) in USA
- 05 Sep 2017 Fujirebio Diagnostics and Morphotek enter into a collaboration agreement to develop and commercialise Farletuzumab companion diagnostic
- 05 Sep 2017 Clinical trials in Ovarian cancer (Diagnosis) in USA (unspecified route)